Illumina, Inc.

ILU.DE

ILU.DEIllumina, Inc. DE flag

Deutsche Börse

78.66

EUR

-2.64

(-3.25%)

-7.12EPS

-11.05P/E

12.46BMarket Cap

Apr 30Next Earn

ISIN

US4523271090

Return %

Stock

S&P500

-34.53

10.92

-73.74

26.22

-65.99

120.31

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	8.55	9.34	11.36	13.73	15.33	16.34	18.85	22.67	24.1	22.03	30.17	29.2	28.51	27.61
Basic EPS, GAAP	0.7	1.23	1	2.61	3.19	3.15	4.97	5.62	6.82	4.46	5.08	-28.05	-7.35	-9.96
Free Cash Flow per Basic Share	2.26	1.71	2.37	2.65	4.44	3.46	3.86	5.76	5.73	6.06	2.25	-0.47	1.78	3.44
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-0.54	0.68	1.68	4.15	7.07	10.13	15.47	20.99	27.68	32.14	36.58	7.29	-0.11	-8.97
Tangible Book Value per Share	5.24	6.66	3.83	3.12	5.68	8.53	12.35	19.24	24.79	24.86	2.51	0.48	1.31	4.45
Basic Weighted Avg Shares	123	123	125	136	145	147	146	147	147	147	150	157	158	159
Sales/Revenue/Turnover	1,056	1,149	1,421	1,861	2,220	2,398	2,752	3,333	3,543	3,239	4,526	4,584	4,504	4,390
Operating Margin (%)	23.72	22.33	17.88	23.82	28.47	24.1	22.02	26.49	27.8	17.91	-2.72	7.72	-4.93	5.44
Depreciation Expense	69	65	98	113	127	141	156	179	188	187	251	394	432	392
Net Income, GAAP	87	151	125	353	462	463	726	826	1,002	656	762	-4,404	-1,161	-1,584
Effective Tax Rate (%)	34.89	32.05	21.35	21.26	21.44	23.71	35	12.53	11.45	23.36	13.8	- -	- -	2.08
Profit Margin (%)	8.21	13.17	8.82	18.98	20.81	19.31	26.38	24.78	28.28	20.25	16.84	-96.07	-25.78	-36.08
Working Capital	1,318	1,482	1,295	1,167	1,486	1,613	2,234	2,686	3,786	3,239	1,620	788	1,039	1,398
LT Debt	807	805	839	987	1,016	1,056	1,182	890	1,836	1,344	2,469	2,231	2,176	2,601
Total Equity	1,075	1,319	1,533	1,463	1,849	2,270	2,749	3,845	4,613	4,694	10,740	6,599	5,745	2,125
Return on Invested Capital (%)	9.57	8.54	8.66	13.36	17.16	13.42	10.22	15.36	13.96	6.71	-1.06	- -	- -	- -
Return on Capital (%)	24.34	21.23	15.61	26.34	25.12	21.07	24.8	20.99	19.07	11.03	11.11	- -	- -	-77.22
Return on Common Equity (%)	- -	- -	85.28	91.47	58.2	36.87	38.77	30.92	28.01	14.92	14.92	-132.83	- -	- -

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	13.11%	7.4%	-1.75%
Net Income, GAAP	-46.51%	-149.73%	-73.64%
Free Cash Flow	-51.93%	-131.97%	-481.08%
Total Cash Common Dividend	- -	- -	- -
Total Equity	20.46%	19.81%	-12.94%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Jacob Thaysen Ph.D.
Full Time Employees: 10,590
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Address: 5200 Illumina Way San Diego CA United States of America 92122
IPO Date: Oct 15, 2007
Website: illumina.com
Similar Companies: Leveljump Healthcare Corp. (JMPHF)
Lumos Diagnostics Holdings Limited (LDXHF)
Sera Prognostics, Inc. (SERA)
Thermo Fisher Scientific Inc. (TMO.NE)
H.U. Group Holdings, Inc. (MRCHF)
Suraksha Diagnostic Limited (SURAKSHA.BO)
Business: Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	8.55	9.34	11.36	13.73	15.33	16.34	18.85	22.67	24.1	22.03	30.17	29.2	28.51	27.61
Basic EPS, GAAP	0.7	1.23	1	2.61	3.19	3.15	4.97	5.62	6.82	4.46	5.08	-28.05	-7.35	-9.96
Free Cash Flow per Basic Share	2.26	1.71	2.37	2.65	4.44	3.46	3.86	5.76	5.73	6.06	2.25	-0.47	1.78	3.44
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-0.54	0.68	1.68	4.15	7.07	10.13	15.47	20.99	27.68	32.14	36.58	7.29	-0.11	-8.97
Tangible Book Value per Share	5.24	6.66	3.83	3.12	5.68	8.53	12.35	19.24	24.79	24.86	2.51	0.48	1.31	4.45
Basic Weighted Avg Shares	123	123	125	136	145	147	146	147	147	147	150	157	158	159
Sales/Revenue/Turnover	1,056	1,149	1,421	1,861	2,220	2,398	2,752	3,333	3,543	3,239	4,526	4,584	4,504	4,390
Operating Margin (%)	23.72	22.33	17.88	23.82	28.47	24.1	22.02	26.49	27.8	17.91	-2.72	7.72	-4.93	5.44
Depreciation Expense	69	65	98	113	127	141	156	179	188	187	251	394	432	392
Net Income, GAAP	87	151	125	353	462	463	726	826	1,002	656	762	-4,404	-1,161	-1,584
Effective Tax Rate (%)	34.89	32.05	21.35	21.26	21.44	23.71	35	12.53	11.45	23.36	13.8	- -	- -	2.08
Profit Margin (%)	8.21	13.17	8.82	18.98	20.81	19.31	26.38	24.78	28.28	20.25	16.84	-96.07	-25.78	-36.08
Working Capital	1,318	1,482	1,295	1,167	1,486	1,613	2,234	2,686	3,786	3,239	1,620	788	1,039	1,398
LT Debt	807	805	839	987	1,016	1,056	1,182	890	1,836	1,344	2,469	2,231	2,176	2,601
Total Equity	1,075	1,319	1,533	1,463	1,849	2,270	2,749	3,845	4,613	4,694	10,740	6,599	5,745	2,125
Return on Invested Capital (%)	9.57	8.54	8.66	13.36	17.16	13.42	10.22	15.36	13.96	6.71	-1.06	- -	- -	- -
Return on Capital (%)	24.34	21.23	15.61	26.34	25.12	21.07	24.8	20.99	19.07	11.03	11.11	- -	- -	-77.22
Return on Common Equity (%)	- -	- -	85.28	91.47	58.2	36.87	38.77	30.92	28.01	14.92	14.92	-132.83	- -	- -

	Mar'24	Jun'24	Sep'24
Total Current Assets	2,583	2,459	2,373
Accounts Receivable, Net	635	641	699
Cash, Cash Equivalents & STI	1,108	994	939
Inventories	584	561	574
Total Current Liabilities	1,474	2,208	975
Payables & Accruals	938	958	430
ST Debt	86	815	73
Deferred Revenue	248	238	235

	Mar'24	Jun'24	Sep'24
ST Debt	86	815	73
LT Borrowings	1,490	1,490	1,988
LT Finance Leases	700	616	613
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	159	159	158
Market Capitalization	21,938	17,112	20,667

Year	Q1	Q2	Q3	Q4	FY
2022	0.55	-3.41	-24.31	-0.88	-28.05
2023	0.02	-1.48	-4.77	-1.1	-7.35
2024	-0.79	-12.5	4.43	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	1,223	1,162	1,115	1,083	4,584
2023	1,087	1,176	1,119	1,122	4,504
2024	1,076	1,112	1,080	- -	- -

Illumina, Inc.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year